{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015859","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.260091+00:00","generated_at":"2026-06-03T08:18:35.653362+00:00","sec_items":["1.01","5.03","2.01","3.02","3.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mangoceuticals acquires patent portfolio for $20M; issues Series C Preferred, eyes Nasdaq compliance","bullets":["Acquired global patent portfolio from Intramont for $20M: 980k Series C Preferred Shares ($19.6M) plus $400k cash over 7 months.","Patents cover preventive oral solutions for cold, respiratory diseases, HPV; plans ODT, toothpaste, mouthwash products.","Series C Preferred: 6% cumulative dividend, $20 stated value, convertible at $10.00/share (2-for-1), with 4.999% conversion cap.","Grant-back license to Intramont with 10% royalty on gross worldwide sales beginning April 2025.","Company believes stockholders' equity now >$5M, regaining Nasdaq minimum equity requirement; still non-compliant on bid price."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015859","json":"https://secwatch.observer/filing/0001493152-24-015859.json","markdown":"https://secwatch.observer/filing/0001493152-24-015859.md","text":"https://secwatch.observer/filing/0001493152-24-015859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:18:35.653362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd1e62d063ee3bd08976799afdec836b5202b9d9","claim":"MANGOCEUTICALS, INC.: Filed a Certificate of Designations establishing the 6% Series C Convertible Cumulative Preferred Stock, designating 6,250,000 shares with specific dividend, liquidation, conversion, voting, protective, and redemption terms (effective 2024-04-19).","evidence_excerpt":"On April 19, 2024, the Company submitted for filing to the Secretary of State of Texas, a Certificate of Designations of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Cumulative Preferred Stock (the “ Series C Designation ”), which was filed with the Secretary of State of Texas on April 23, 2024, effective as of April 19, 2024.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-19"}],"fact_type":"governance_change"},{"claim_id":"392bef86c2ce4de9619f7d09df04816d5c0ec0f8","claim":"MANGOCEUTICALS, INC. completed an acquisition involving Intramont Technologies, Inc. for $20,000,000 (closed 2024-04-24).","evidence_excerpt":"infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the “ Patents ”), in consideration for $20,000,000, which is payable to Intramont by (a) the issuance of 980,000 shares of the Company’s newly designated 6% Series C Convertible Preferred Stock (the “ Series C Preferred Stock","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Intramont Technologies, Inc."},{"label":"Consideration","value":"$20,000,000"},{"label":"Closing","value":"2024-04-24"}],"fact_type":"ma_transaction"},{"claim_id":"b12a1a8d21185b01cede1789580921f097eba2a1","claim":"MANGOCEUTICALS, INC. entered into Patent Purchase Agreement with Intramont Technologies, Inc. valued at $20,000,000 (effective 2024-04-24).","evidence_excerpt":"Mangoceuticals, Inc., a Texas corporation (the “ Company ”, “ we ” and “ us ”), entered into a Patent Purchase Agreement (the “ IP Purchase Agreement ”), with Intramont Technologies, Inc. (“ Intramont ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224015859/0001493152-24-015859-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Intramont Technologies, Inc."},{"label":"Value","value":"$20,000,000"},{"label":"Effective","value":"2024-04-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}